| Message: | Anti-Estrogen Steroids Faslodex for Cancer Treatment Fulvestrant CAS 129453-61-8
1. Quick Detail:
Product Name Fulvestrant
Alias Faslodex
CAS 129453-61-8
Assay 97.0%~103.0%
Appearance White Powder
Molecular Formula C32H47F5O3S
Molecular weight 606.77
Grade Pharmaceutical Grade
Storage Shading, Confined Preservation
2. Description:
Fulvestrant (trade name Faslodex, by AstraZeneca) is a drug treatment of hormone receptor-positive metastaticbreast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.
3. Applications:
Fulvestrant is a selective estrogen receptor degrader (SERD). It is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Fulvestrant provides effective second-line therapy in metastatic or locally advanced breast cancer for postmenopausal women who relapse or progress after previous endocrine therapy.
Contact Person: Jack
Sky-pe: PharChemSteroid
Email: jack@chembj.com
WhatsApp: +8617327096097 |
my account
